The bill proposes the enactment of sections 3902.65 and 5164.13 of the Revised Code, mandating that health benefit plans and the Medicaid program provide coverage for biomarker testing. The legislation defines "biomarker" and "biomarker testing," and outlines the purposes for which such testing must be covered, including diagnosis, treatment, and ongoing monitoring of diseases or conditions. Coverage is contingent upon the testing being deemed medically necessary by a qualified healthcare provider and supported by medical or scientific evidence. The bill also emphasizes the need for health plans to limit disruptions in care and outlines the appeal process for coverage determinations.

Additionally, the bill clarifies that it does not require coverage for biomarker testing for screening purposes. The intent of the General Assembly is to ensure that appropriate biomarker testing is covered, aiming to improve health outcomes and achieve long-term healthcare cost savings for Ohioans. The legislation seeks to prevent manufacturers and administrators of biomarker tests from significantly increasing prices due to the new coverage requirements.